Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
2,861
Views
6
CrossRef citations to date
0
Altmetric
Real World Evidence
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
Tilman Hans Steinmetza Center for Hematology and Oncology, Cologne, GermanyCorrespondence[email protected]
https://orcid.org/0000-0001-8580-3109
Moushmi Singhb Amgen Limited, Uxbridge, UK
, Andrea Lebiodac Amgen GmbH, Munich, Germany
, Leah Finkd Kantar, Health Division, Paris, France
, Martina Schoehlc Amgen GmbH, Munich, Germany
, Achim Riethc Amgen GmbH, Munich, Germany
, Sebastian Gonzalez-McQuiree Amgen (Europe) GmbH, Rotkreuz, Switzerland
& Monika Engelhardtf Faculty of Freiburg, University Hospital of Freiburg, Freiburg, Germany
show all
Pages 114-122
|
Received 28 Aug 2020, Accepted 14 Dec 2020, Published online: 18 Jan 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.